Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Language and Cognition01:27

Language and Cognition

Language serves as a bridge between ideas and communication, influencing how individuals perceive and interact with the world. Psychologists have long debated whether language shapes thought or vice versa. This discussion gained grip with Edward Sapir and Benjamin Lee Whorf in the 1940s, who proposed that language determines thought, a concept known as linguistic determinism. They suggested that the vocabulary and structure of a language influence how its speakers think and perceive reality.
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.

Journal of neurology·2025
Same author

Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.

Journal of neurology·2024
Same author

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal of medical economics·2023
Same author

Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors.

Multiple sclerosis and related disorders·2023
Same author

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2022
Same author

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

BMC medical research methodology·2022

Related Experiment Video

Updated: Jun 30, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Cognitive impairment in multiple sclerosis.

F Patti1

  • 1Department of Neurology, University of Catania, Catania, Italy. patti@unict.it

Multiple Sclerosis (Houndmills, Basingstoke, England)
|September 23, 2008
PubMed
Summary
This summary is machine-generated.

Cognitive impairment is a common symptom of multiple sclerosis (MS). Further research is needed to assess cognitive function and develop effective therapies for MS-related cognitive decline.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Related Experiment Videos

Last Updated: Jun 30, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Area of Science:

  • Neuroscience
  • Clinical Neurology

Background:

  • Cognitive impairment is a prevalent and disabling symptom in multiple sclerosis (MS).
  • MS-related cognitive deficits significantly impact patients' quality of life.
  • Current clinical practice and trials rarely assess cognitive function in MS patients due to perceived challenges.

Purpose of the Study:

  • To highlight the need for routine cognitive assessment in multiple sclerosis (MS).
  • To emphasize the lack of established guidelines for assessing MS-associated cognitive impairment.
  • To underscore the necessity for further research into managing cognitive decline in MS.

Main Methods:

  • Review of existing literature on cognitive impairment in MS.
  • Analysis of the role of disease-modifying drugs (DMDs) in MS-related cognitive function.
  • Identification of gaps in current research and clinical practice regarding cognitive assessment in MS.

Main Results:

  • Cognitive impairment is a significant, yet under-assessed, aspect of multiple sclerosis.
  • Disease-modifying drugs (DMDs) show potential for cognitive benefits in MS, but evidence is limited.
  • There is a lack of comprehensive studies and clear guidelines for cognitive evaluation and management in MS.

Conclusions:

  • Further research is crucial to identify and treat patients with or at risk of cognitive impairment in MS.
  • Standardized cognitive assessments are needed in clinical practice and trials for multiple sclerosis.
  • Effective therapeutic strategies are required to mitigate the impact of cognitive decline in MS patients.